In the Claims

Applicant has submitted a new complete claim set indicating marked up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

1. (Currently amended) A compound of formula (I)



(I)

or a salt thereof, or a solvate thereof, wherein;

X represents NR_b, wherein R_b represents hydrogen, unsubstituted or substituted C_{1-6} alkyl or unsubstituted or substituted C_{1-6} alkylcarbonyl;

Y and Z each independently represent nitrogen, CH, CR_1 or CR_2;

A represents an unsubstituted or substituted aryl group;

R_a represents -C(O)NR_sR_t wherein R_s ~~and R_t each independently~~ represents ~~hydrogen, unsubstituted or substituted C_{1-6} alkyl, unsubstituted or substituted C_{3-8} cycloalkyl, unsubstituted or substituted C_{1-6} alkenyl, unsubstituted or~~ substituted aryl, unsubstituted or substituted aryl C_{1-6} alkyl, unsubstituted or substituted heterocyclyl or an unsubstituted ~~or substituted~~ heterocyclyl C_{1-6} alkyl group, ~~or R_s and R_t together with the nitrogen to which they are attached form a heterocyclyl group~~ R_t represents hydrogen, unsubstituted or substituted C_{1-6} alkyl, unsubstituted or substituted C_{3-8} cycloalkyl, unsubstituted or substituted C_{1-6} alkenyl;

R_1 and R_2 each independently represents hydrogen, hydroxy, amino, C_{1-6} alkoxy, unsubstituted or substituted aryloxy, unsubstituted or substituted benzyloxy, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, halo, trifluoromethyl, trifluoromethoxy, nitro, C_{1-6} alkyl, carboxy, alkoxycarbonyl, carbamoyl, C_{1-6} alkylcarbamoyl, or R_1 and R_2 together represent methylenedioxy, -$(CH=CH)_{2-3}$-, carbonyldioxy or carbonyldiamino.

2. (Previously presented) A process for the preparation of a compound of formula (I) according to claim 1, or a salt thereof or a solvate thereof, wherein said process comprises the steps of:

(a) amidation of a carboxylic acid having the formula:



wherein X', Y', Z', A', $R_{1'}$ and $R_{2'}$ each respectively represent X, Y, Z, A, R_1 and R_2 as defined in claim 1 or a protected form thereof,

with an amine having the formula:

$$HNR_{s'}R_{t'}$$

wherein $R_{s'}$ and $R_{t'}$ each respectively represent R_s and R_t as defined in claim 1 or a protected form thereof, and

(b) optionally preparing a salt or solvate thereof.

3. (Previously presented) A process for the preparation of a compound of formula (I) according to claim 2, further comprising the steps of :

(i) converting the compound of formula (I) formed in step (a) or step (b) into another compound of formula (I);

(ii) removing any protecting group; and

(iii) preparing a salt or a solvate thereof.

4. (Previously presented) A process for the preparation of a compound of formula (I) according to claim 1, or a salt thereof or a solvate thereof, wherein said process comprises cleavage of a compound of formula (VIII) at the N-Resin bond



(VIII)

wherein X′, Y′, Z′, A′, $R_{1'}$, $R_{2'}$ and $R_{s'}$ each respectively represent X, Y, Z, A, R_1, R_2 and R_s as defined in claim 1.

5. (Previously presented) A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

6. (Canceled)

7. (Original) A method for the treatment of osteoporosis and related osteopenic diseases in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

8. (Currently amended) A method for the treatment of tumours, ~~viral conditions, ulcers, autoimmune diseases and transplantation, for the treatment or prevention of hypercholesterolemic and atherosclerotic diseases, AIDS, Alzheimer's disease, and angiogenic diseases~~ in a human or non-human mammal, which method comprises administering an effective, non-toxic, amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

9-15. (Canceled)

16. (Previously presented) The method according to claim 8, wherein the treatment of tumours comprises treatment of renal cancer, melanoma, colon cancer, lung cancer and leukemia.

17-19. (Canceled)

20. (New) A compound of formula (I)



(I)

or a salt thereof, or a solvate thereof, wherein;

X represents NR_b, wherein R_b represents hydrogen, unsubstituted or substituted C_{1-6} alkyl or unsubstituted or substituted C_{1-6} alkylcarbonyl;

Y and Z each independently represent nitrogen, CH, CR_1 or CR_2;

A represents an unsubstituted or substituted aryl group;

R_a represents $-C(O)NR_sR_t$ wherein

R_s represents substituted aryl, unsubstituted or substituted aryl C_{1-6} alkyl, unsubstituted or substituted heterocyclyl or an unsubstituted heterocyclyl C_{1-6} alkyl group;

R_t represents hydrogen, unsubstituted or substituted C_{1-6} alkyl, unsubstituted or substituted C_{3-8} cycloalkyl, unsubstituted or substituted C_{1-6} alkenyl;

R_1 and R_2 each independently represents hydrogen, hydroxy, amino, C_{1-6} alkoxy, unsubstituted or substituted aryloxy, unsubstituted or substituted benzyloxy, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, halo, trifluoromethyl, trifluoromethoxy, nitro, C_{1-6} alkyl, carboxy,

alkoxycarbonyl, carbamoyl, C_{1-6} alkylcarbamoyl, or R_1 and R_2 together represent methylenedioxy, $-(CH=CH)_{2-3}-$, carbonyldioxy or carbonyldiamino,

wherein:

said heterocyclic groups are selected from aromatic and non-aromatic, single and fused rings containing 4-7 ring members and up to four heteroatoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or substituted by up to three substituents;

said substituted aryl and substituted heterocyclyl groups are substituted with up to three substituents selected from aryl, arylcarbonyl, alkylthio, halo, alkyl, alkenyl, substituted alkenyl, arylalkyl, alkoxy, alkoxyalkyl, haloalkyl, haloalkyloxy, hydroxy, hydroxyalkyl, nitro, amino, cyano, cyanoalkyl, mono-and di-N-alkylamino, acyl, acylamino, N-alkylacylamino, acyloxy, carboxy, carboxyalkyl, carboxyalkenyl, carbamoyl, mono-and di-N-alkylcarbamoyl, alkoxycarbonyl, aryloxy, arylthio, aralkyloxy, aryloxycarbonyl, aminosulphonyl, alkylaminosulphonyl, alkylthio, alkylsulphonyl, cycloalkyl, heterocyclyl, or a group $-NR_uR_v$ wherein R_u and R_v each independently represent hydrogen, alkyl or alkylcarbonyl;

said substituted alkyl, alkyl-containing, and alkenyl groups are substituted with up to three groups selected from aryl, heterocyclyl, alkylthio, alkoxy, arylalkoxy, amino, mono-or di-alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, mono or dialkylaminosulphonyl, aminosulphonyl, cyano, alkylcarbonylamino, arylcarbonylamino, hydroxy, and halogen.